Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEVATE: Open-label phase 1b/2 umbrella study of elacestrant combinations in metastatic breast cancer
MOH_2023-08-22_012707Phase 2Recruiting
- Sponsor
- Stemline Therapeutics
- Start
- Apr 2023
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of elacestrant in breast cancer (6 arms), sponsored by Stemline Therapeutics. Primary endpoints: Recommended phase 2 dose, Safety and 1 more. Started Apr 2023; status: recruiting.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2023-08-22_012707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-08-22_012707.